Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease. In patients with IPF, cough is one of the most disabling symptoms and is an independent predictor of disease progression [1–3]. Cough in IPF is often non-responsive to antitussive therapy [4], and studies on cough are scarce and have unfortunately not yet resulted in effective treatments. Several observations suggest that pirfenidone, an anti-fibrotic drug, might decrease cough [5, 6]. We aimed to measure objectively the effect of pirfenidone on cough in patients with IPF and substantial cough. In addition, we assessed the effect of pirfenidone on subjective cough and quality of life (QoL) measures. In patients with IPF, pirfenidone reduces objective 24-h cough counts and improves subjective measures of cough http://ow.ly/iiGu30f7Pea

中文翻译：

---

吡非尼酮对特发性肺纤维化患者咳嗽的影响

特发性肺纤维化 (IPF) 是一种进行性、致命的肺部疾病。在 IPF 患者中，咳嗽是最致残的症状之一，并且是疾病进展的独立预测因子 [1-3]。IPF 中的咳嗽通常对镇咳治疗无反应 [4]，而且关于咳嗽的研究很少，遗憾的是尚未产生有效的治疗方法。一些观察结果表明，吡非尼酮是一种抗纤维化药物，可能会减少咳嗽 [5, 6]。我们旨在客观地衡量吡非尼酮对 IPF 和剧烈咳嗽患者咳嗽的影响。此外，我们评估了吡非尼酮对主观咳嗽和生活质量 (QoL) 指标的影响。在 IPF 患者中，吡非尼酮可减少客观 24 小时咳嗽计数并改善咳嗽的主观测量值 http://ow.ly/iiGu30f7Pea